A Study of ELX-02 in Patients With Alport Syndrome

Status Recruiting

Clinical Trial Summary

This is a Phase 2 open label pilot study to evaluate the safety and efficacy of subcutaneously administered ELX-02 in patients with X-linked or autosomal recessive Alport Syndrome with Col4A5 and Col4A3/4 nonsense mutation. In total, up to 8 participants, with a minimum of 3 adults, will be enrolled in the trial. The study will be comprised of the following periods for each participant: - a Screening period of up to 6 weeks (42 days) - a total Treatment Period of 8 weeks (60 days) - a safety/efficacy Follow-up Period of 12 weeks (90 days) after the last treatment The Treatment Period will be a treatment of ELX-02 0.75 mg/kg SC QD for 8 weeks.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05448755
Study type	Interventional
Source	Eloxx Pharmaceuticals, Inc.
Contact	Eloxx Pharmaceuticals
Phone	+1(781) 577-5300
Email	info@eloxxpharma.com
Status	Recruiting
Phase	Phase 2
Start date	November 28, 2022
Completion date	May 30, 2023

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01696253` - Multi-center Controlled Clinical Trials in Alport Syndrome-A Feasibility Study
Terminated	`NCT01602835` - Human Urine Sample Collection for Alport Nephropathy Biomarker Studies	N/A
Recruiting	`NCT00481130` - Alport Syndrome Treatments and Outcomes Registry
Recruiting	`NCT05687474` - Baby Detect : Genomic Newborn Screening
Recruiting	`NCT06065852` - National Registry of Rare Kidney Diseases
Recruiting	`NCT06274489` - A Study to Evaluate Setanaxib in Patients With Alport Syndrome	Phase 1/Phase 2
Terminated	`NCT02855268` - Study of Lademirsen (SAR339375) in Patients With Alport Syndrome	Phase 2
Recruiting	`NCT06226896` - Effects of Dapagliflozin on Progression of Alport Syndrome
Recruiting	`NCT05927467` - Eurbio-Alport (RaDiCo Cohort) (RaDiCo Eurbio-Alport)
Terminated	`NCT03749447` - An Extended Access Program for Bardoxolone Methyl in Patients With CKD (EAGLE)	Phase 3
Completed	`NCT03019185` - A Phase 2/3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients With Alport Syndrome - CARDINAL	Phase 2/Phase 3
Completed	`NCT01705132` - Urinary Biomarkers of the Progression of Alport Kidney Disease	N/A
Recruiting	`NCT05267262` - Study to Evaluate R3R01 in Patients With Alport Syndrome and Patients With Focal Segmental Glomerulosclerosis	Phase 2
Completed	`NCT00622544` - A Prospective Study of Microalbuminuria in Untreated Boys With Alport Syndrome
Recruiting	`NCT02378805` - European Alport Therapy Registry - European Initiative Towards Delaying Renal Failure in Alport Syndrome
Not yet recruiting	`NCT05655728` - Treatment With Metformin in Chinese Children With Alport Syndrome	Phase 4
Completed	`NCT00309257` - Effects of an Intensified Treatment With ACE-I,ATA II and Statins in Alport Syndrome	Phase 2
Not yet recruiting	`NCT05133050` - Safety and Efficacy of ACEI in Alport Syndrome Patients With COL4A3/COL4A4/COL4A5 Variants	N/A
Recruiting	`NCT04947813` - Genotype-Phenotype Correlations in Patients With Alport Syndrome
Active, not recruiting	`NCT04573920` - Atrasentan in Patients With Proteinuric Glomerular Diseases	Phase 2